⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9618300 | 0.84 | CES2 (0.32) | — | |
| SCHEMBL11630550 | 0.84 | ALDH1A1 (0.33) | — | |
| SCHEMBL28340395 | 0.81 | CES2 (0.36) | — | |
| SCHEMBL1583583 | 0.77 | — | — | |
| SCHEMBL1895685 | 0.77 | — | — | |
| SCHEMBL28112728 | 0.76 | POLB (0.30) | — | |
| SCHEMBL28080661 | 0.76 | — | — | |
| SCHEMBL1097334 | 0.75 | — | — | |
| SCHEMBL1681615 | 0.75 | CYP4F2 (0.44) | — | |
| SCHEMBL8861737 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114380888-A | Difluoro-substituted romidepsin analogue, and preparation method and application thereof | 复旦大学 | 2022-04-22 | — | — | CN | claimed |
| US-11980626-B2 | Compositions for treatment of breast and prostate cancer | KEMBI THERAPEUTICS PTY LTD (AU) | 2024-05-14 | — | — | US | disclosed |
| CN-114380888-B | Difluoro substituted romidepsin analogue, preparation method and application thereof | 复旦大学 | 2024-02-27 | — | — | CN | disclosed |
| US-20230312486-A1 | POLYMORPHIC FORMS OF A ROR INHIBITING COMPOUND AND PROCESSES FOR ITS PREPARATION | GLENMARK SPECIALTY S.A. (CH) | 2023-10-05 | — | — | US | disclosed |
| EP-4208449-A1 | POLYMORPHIC FORMS OF A RORGAMMA INHIBITING COMPOUND AND PROCESSES FOR ITS PREPARATION | Glenmark Specialty S.A. (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20220387394-A1 | METHODS OF TREATING CANCER USING ANDROGEN RECEPTOR ANTAGONISTS | GARVAN INSTITUTE OF MEDICAL RES (AU) | 2022-12-08 | — | — | US | disclosed |
| EP-4048265-A1 | METHODS OF TREATING CANCER USING ANDROGEN RECEPTOR ANTAGONISTS | Garvan Institute of Medical Research (AU) | 2022-08-31 | — | — | EP | disclosed |
| CN-114380888-A | Difluoro-substituted romidepsin analogue, and preparation method and application thereof | 复旦大学 | 2022-04-22 | — | — | CN | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210292410-A1 | TREATMENT PARADIGM FOR AN ANTI-CD19 ANTIBODY AND VENETOCLAX COMBINATION TREATMENT | INCYTE CORPORATION | 2021-09-23 | — | — | US | disclosed |
| US-5411974-A | Thiazoline derivatives, treatment of amnesia | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-05-02 | — | — | US | disclosed |
| US-5401760-A | Thiazoline derivative for treating amnesia | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-03-28 | — | — | US | disclosed |
| EP-0345428-B1 | Anti-amnesic pyrrolidine derivatives | ONO PHARMACEUTICAL CO (JP) | 1995-01-18 | — | — | EP | disclosed |
| US-5212191-A | Thiazoline derivatives for treatment of amnesia | ONO PHARMACEUTICAL CO., LTD. (JP) | 1993-05-18 | — | — | US | disclosed |
| US-5053414-A | Thiazolidine derivatives, enzyme inhibitors; amnesia | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-10-01 | — | — | US | disclosed |
| EP-0371179-A1 | Novel analogs of peptidase substrates | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-06-06 | — | — | EP | disclosed |
| EP-0368719-A2 | Novel analogs of peptidase substrates | MERRELL PHARMACEUTICALS INC. (US) | 1990-05-16 | — | — | EP | disclosed |
| EP-0362002-A1 | HIV protease inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-04-04 | — | — | EP | disclosed |
| EP-0345428-A1 | Anti-amnesic pyrrolidine derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-12-13 | — | — | EP | disclosed |
| EP-0211354-A2 | Nucleosides and their use as antineoplastic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-02-25 | — | — | EP | disclosed |